Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Albendazole Tablets USP, 200 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), LAlbenza Tablets, 200 mg, of Impax Laboratories, Inc. (Impax). Albendazole tablets are indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium. It is also indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus. Powered by Capital Market - Live

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Luxiq Foam of Norvium Bioscience, LLC (Norvium). Betamethasone valerate foam is a medium potency topical corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp. The company has a cumulative total of 213 ANDA approvals (185 final approvals and 28 tentative approvals) from USFDA. Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. The pharmaceutical company's consolidated net profit increased 11.69% to Rs 134.71 crore in Q1 FY25 as compared to Rs 120.60 crore posted in Q1 FY24. Revenue from operations grew 5.09% year on year (YoY) to Rs 1,561.73 crore in the quarter ended 30 June 2024.Powered by Capital Market - Live

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Luxiq Foam of Norvium Bioscience, LLC (Norvium). Betamethasone valerate foam is a medium potency topical corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp. The company has a cumulative total of 213 ANDA approvals (185 final approvals and 28 tentative approvals) from USFDA. Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. The pharmaceutical company's consolidated net profit increased 11.69% to Rs 134.71 crore in Q1 FY25 as compared to Rs 120.60 crore posted in Q1 FY24. Revenue from operations grew 5.09% year on year (YoY) to Rs 1,561.73 crore in the quarter ended 30 June 2024. The scrip slipped 1.50% to settle at Rs 1,100.55 on Friday, 23 August 2024. Powered by Capital Market - Live

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Betamethasone Valerate Foam, 0.12%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Luxiq Foam, 0.12%, of Norvium Bioscience, LLC (Norvium). Betamethasone valerate foam, 0.12% is a medium potency topical corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp. Refer label for a detailed indication. Alembic has a cumulative total of 213 ANDA approvals (185 final approvals and 28 tentative approvals) from USFDA.Powered by Capital Market - Live

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Pradaxa Capsules of Boehringer Ingelheim Pharmaceuticals, Inc. (Boehringer). Dabigatran Etexilate Capsules are indicated for prophylaxis of deep vein thrombosis and pulmonary embolism following hip replacement surgery. Alembic has a cumulative total of 211 ANDA approvals (183 final approvals and 28 tentative approvals) from USFDA,' the company said in a statement. Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. The pharmaceutical company's consolidated net profit increased 11.69% to Rs 134.71 crore in Q1 FY25 as compared to Rs 120.60 crore posted in Q1 FY24. Revenue from operations grew 5.09% year on year (YoY) to Rs 1,561.73 crore in the quarter ended 30 June 2024. Powered by Capital Market - Live

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Dabigatran Etexilate Capsules, 110 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Pradaxa Capsules, 110 mg of Boehringer Ingelheim Pharmaceuticals, Inc. (Boehringer). Dabigatran Etexilate Capsules 110 mg are indicated for prophylaxis of deep vein thrombosis and pulmonary embolism following hip replacement surgery. Alembic has a cumulative total of 211 ANDA approvals (183 final approvals and 28 tentative approvals) from USFDA. Powered by Capital Market - Live

Steel Authority of India Ltd, IFCI Ltd, Coffee Day Enterprises Ltd and Orient Cement Ltd are among the other losers in the BSE's 'A' group today, 09 August 2024.Alembic Pharmaceuticals Ltd lost 6.26% to Rs 1138.15 at 14:46 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 36635 shares were traded on the counter so far as against the average daily volumes of 37981 shares in the past one month.Steel Authority of India Ltd crashed 5.96% to Rs 129.3. The stock was the second biggest loser in 'A' group.On the BSE, 47.15 lakh shares were traded on the counter so far as against the average daily volumes of 19.79 lakh shares in the past one month.IFCI Ltd tumbled 5.60% to Rs 70.96. The stock was the third biggest loser in 'A' group.On the BSE, 53.78 lakh shares were traded on the counter so far as against the average daily volumes of 86.01 lakh shares in the past one month.Coffee Day Enterprises Ltd pared 5.28% to Rs 46.5. The stock was the fourth biggest loser in 'A' group.On the BSE, 8.46 lakh shares were traded on the counter so far as against the average daily volumes of 2.93 lakh shares in the past one month.Orient Cement Ltd shed 5.26% to Rs 331.4. The stock was the fifth biggest loser in 'A' group.On the BSE, 1.79 lakh shares were traded on the counter so far as against the average daily volumes of 2.09 lakh shares in the past one month.Powered by Capital Market - Live

Net profit of Alembic Pharmaceuticals rose 11.70% to Rs 134.71 crore in the quarter ended June 2024 as against Rs 120.60 crore during the previous quarter ended June 2023. Sales rose 5.09% to Rs 1561.73 crore in the quarter ended June 2024 as against Rs 1486.15 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales1561.731486.15 5 OPM %15.1613.37 - PBDT226.07195.94 15 PBT157.03129.76 21 NP134.71120.60 12 Powered by Capital Market - Live

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Acitretin Capsules USP, 10 mg, 17.5 mg, and 25 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Soriatane Capsules, 10 mg, 17.5 mg, and 25 mg, of Stiefel Laboratories, Inc. (Stiefel). Acitretin capsules are indicated for the treatment of severe psoriasis in adults. Refer label for a detailed indication. Acitretin Capsules USP, 10 mg, 17.5 mg, and 25 mg have an estimated market size of US$ 21 million for twelve months ending June 2024 according to IQVIA. Alembic has a cumulative total of 212 ANDA approvals (184 final approvals and 28 tentative approvals) from USFDA.Powered by Capital Market - Live

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Soriatane Capsules of Stiefel Laboratories, Inc. Acitretin capsules are indicated for the treatment of severe psoriasis in adults. Acitretin Capsules USP has an estimated market size of US$ 21 million for twelve months ending June 2024 according to IQVIA. Alembic has a cumulative total of 212 ANDA approvals (184 final approvals and 28 tentative approvals) from US FDA. Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. The company manufactures and markets generic pharmaceutical products all over the world. The company reported 16.78% increase in consolidated net profit to Rs 178.21 crore on 7.85% rise in revenue from operations to Rs 1,516.98 in Q4 FY24 over Q4 FY23. Powered by Capital Market - Live